Read our Annual Report 2018
MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.
First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic pipeline.
MorphoSys's vision
08/07/2019
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule...
03/07/2019
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program...
03/07/2019
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a...
24/06/2019
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
24/06/2019
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive...
22/06/2019
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab...
14/06/2019
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for...
